These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 327247)

  • 21. Drugs for improvement of cerebral function in the elderly.
    Med Lett Drugs Ther; 1976 Apr; 18(9):38-9. PubMed ID: 1264019
    [No Abstract]   [Full Text] [Related]  

  • 22. Preventing senile dementia: hope for the future.
    Kent S
    Geriatrics; 1981 Sep; 36(9):130, 133, 135-6. PubMed ID: 7274675
    [No Abstract]   [Full Text] [Related]  

  • 23. Mental decline in the elderly: pharmacotherapy (ergot alkaloids versus papaverine).
    Rosen HJ
    J Am Geriatr Soc; 1975 Apr; 23(4):169-74. PubMed ID: 803997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapy of senile dementia of the Alzheimer type and multi-infarct dementia].
    Gertz HJ; Kanowski S
    Nervenarzt; 1983 Sep; 54(9):444-54. PubMed ID: 6138718
    [No Abstract]   [Full Text] [Related]  

  • 25. Double-blind clinical and psychologic study of ergoloid mesylates (Hydergine) in subjects with senile mental deterioration.
    van Loveren-Huyben CM; Engelaar HF; Hermans MB; van der Bom JA; Leering C; Munnichs JM
    J Am Geriatr Soc; 1984 Aug; 32(8):584-8. PubMed ID: 6379022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does papaverine affect brain dopamine?
    Branconnier RJ; Cole JO; Ghazvinian S
    Ann Neurol; 1982 Jul; 12(1):64. PubMed ID: 7114820
    [No Abstract]   [Full Text] [Related]  

  • 27. [Efficacy and tolerance of long-term naftidrofuryl treatment of patients with senile dementia. Controlled study versus placebo].
    Cucinotta D; Dall'Asta D; Benaglia F; Ciotti G; Nicora M; Passeri M
    G Clin Med; 1987 Apr; 68(4):211-7. PubMed ID: 3301493
    [No Abstract]   [Full Text] [Related]  

  • 28. [Dihydroergocristine in the treatment of organic brain psychosyndrome. Dose-finding study against placebo].
    Milvio C
    Arzneimittelforschung; 1992 Nov; 42(11A):1399-402. PubMed ID: 1492861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Eutergin in the treatment of chronic cerebrovascular disturbance patterns (author's transl)].
    Prosenz P
    Aktuelle Gerontol; 1980 Jun; 10(6):245-51. PubMed ID: 6109460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Co-dergocrinmesylate in elderly hypertensive patients].
    Bock KD; Welzel D; Dennler HJ
    MMW Munch Med Wochenschr; 1982 Dec; 124(48):1095-8. PubMed ID: 6817133
    [No Abstract]   [Full Text] [Related]  

  • 31. The treatment of senile dementia associated with cerebrovascular insufficiency: a comparative study of buflomedil and dihydrogenated ergot alkaloids.
    Jansen W; Bruckner GW; Jansen P
    J Int Med Res; 1985; 13(1):48-53. PubMed ID: 3884411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The use of 1-acetylcarnitine in (presenile and senile) Alzheimer's disease. Preliminary results].
    Acierno G
    Clin Ter; 1983 Apr; 105(2):135-45. PubMed ID: 6345054
    [No Abstract]   [Full Text] [Related]  

  • 33. [Controlled double-blind study of the clinical equivalent of two posologic regimens of Hydergine: 1 x 4,5mg compared to 3 x 1,5mg per day].
    Piguet PV; Zoufal Z
    Rev Med Suisse Romande; 1981 Feb; 101(2):157-63. PubMed ID: 7015453
    [No Abstract]   [Full Text] [Related]  

  • 34. [Controlled clinical study of use of dihydroergocristine in cerebral and periferal vascular disorders].
    Calisti G; Biscarini L; Miseo A
    Clin Ter; 1977 Nov; 83(4):371-86. PubMed ID: 414875
    [No Abstract]   [Full Text] [Related]  

  • 35. Helping to make the final years meaningful for the elderly residents of nursing homes.
    Einspruch BC
    Dis Nerv Syst; 1976 Aug; 37(8):439-42. PubMed ID: 821734
    [No Abstract]   [Full Text] [Related]  

  • 36. Ergoloid mesylates vs. Alzheimer's: the latest round.
    Walker C
    Geriatrics; 1990 Dec; 45(12):22, 24. PubMed ID: 2253892
    [No Abstract]   [Full Text] [Related]  

  • 37. Electroencephalographic and clinical changes as correlated in geriatric patients treated three months with an ergot alkaloid preparation.
    Matejcek M; Knor K; Piguet PV; Weil C
    J Am Geriatr Soc; 1979 May; 27(5):198-202. PubMed ID: 372291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapy with lecithin and ergoloid mesylates for Alzheimer's disease.
    Jenike MA; Albert MS; Heller H; LoCastro S; Gunther J
    J Clin Psychiatry; 1986 May; 47(5):249-51. PubMed ID: 3700343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ergoloid mesylates for senile dementias: unanswered questions.
    Hollister LE; Yesavage J
    Ann Intern Med; 1984 Jun; 100(6):894-8. PubMed ID: 6372566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydergine for schizophrenia.
    Cohen MR; Pary R; Burns R
    J Clin Psychiatry; 1987 Jan; 48(1):39-40. PubMed ID: 3542983
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.